Physician profile
Mark Delacure
NPI 1326049453
$2,048.85
in general payments reported to CMS, 2019-2025
12 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2021: $127 · 2023: $459 · 2024: $562 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $427.14 | 2019-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Rti Surgical, INC | $288.72 | 2023-2024 | |
| Abbvie INC. | $232.18 | 2023-2024 | Artia |
| Intuitive Surgical, INC. | $202.78 | 2019 | |
| Baxter Healthcare | $180.77 | 2025 | Artiss, Tisseel |
| Integra Lifesciences Corporation | $144.67 | 2025 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Aroa Biosurgery Incorporated | $139.50 | 2025 | |
| Avita Medical Americas, LLC | $128.41 | 2024 | |
| Axogen | $105.15 | 2024 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Nerve Protector |
| Dilon Technologies, INC. | $95.94 | 2024 | Hemoblast Bellows |
| Tactile Systems Technology INC | $87.00 | 2021 | |
| Solventum Corporation | $16.59 | 2025 | Activ.A.C. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Delacure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.